

Atrial fibrillation ablation versus heart rate control using conduction system pacing with ablation of the atrioventricular node

Submission date 25/07/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 05/08/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 09/06/2025	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Atrial fibrillation (AF) impacts heart function by causing a loss of contraction and deteriorating pump function due to the irregular and often rapid heart rate. The coexistence of AF with heart failure (HF) increases the risk of hospitalization and death. Treatment strategies involve drugs to slow down heart rate or to maintain normal rhythm, catheter intervention to maintain normal rhythm (AF ablation by pulmonary vein isolation), or implantation of a pacemaker with catheter ablation of the atrioventricular node (AVNA) to allow the pacemaker to regulate the heart rate. Conduction system pacing (CSP) involves implanting the pacemaker lead directly into the heart's natural electrical conduction system, maintaining a close to normal contraction of the heart (which allows preservation of pump function).

This study evaluates a strategy of AF ablation against CSP combined with AVNA in patients with AF and HF, as these treatments have never been directly compared. The aim is to determine whether CSP with AVNA has similar rates of heart failure hospitalization and death compared to AF ablation.

Who can participate?

Patients aged 60 years and over who have persistent AF (which is continuously present for over 7 days) and HF (with at least one hospitalization or emergency room / HF clinic visit for HF in the past 2 years and elevated blood markers for HF during this interval)

What does the study involve?

Patients are randomly allocated to either AF ablation or to pacemaker implantation with CSP and AVNA. Both these treatments are performed in routine clinical practice. The patients are then followed up for at least 1 year for clinical events (hospitalizations, deaths), as well as other criteria such as quality of life.

What are the possible benefits and risks of participating?

Participants will be closely followed up. The risks involved are those of the routine procedures of the study.

Where is the study run from?
University Hospital of Geneva (Switzerland)

When is the study starting and how long is it expected to run for?
August 2022 to October 2028

Who is funding the study?
Swiss National Science Fund (Switzerland)

Who is the main contact?
Prof. Haran Burri, haran.burri@hug.ch

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Prof Haran Burri

ORCID ID
<https://orcid.org/0000-0002-4393-5338>

Contact details
Cardiology Departement
University Hospital of Geneva
Rue Gabrielle Perret Gentil 4
Geneva
Switzerland
1211
+41 (0)22 372 72 00
haran.burri@hug.ch

Additional identifiers

ClinicalTrials.gov (NCT)
NCT06207383

Protocol serial number
SNF_2024-D0031

Study information

Scientific Title
Catheter Ablation of Atrial fibrillation versus atrioventricular nodal ablation with Conduction System pacing in persistent atrial fibrillation and heart failure (ABACUS)

Acronym
ABACUS

Study objectives

The investigation seeks primarily to determine whether Conduction System Pacing + Atrioventricular Nodal Ablation (CSP+AVNA) is superior to atrial fibrillation (AF) ablation to reduce the incidence of cardiovascular hospitalization (CVH) or mortality, and whether it is non-inferior to reduce heart failure hospitalization (HFH) or mortality, in patients with persistent atrial fibrillation (AF) and heart failure (HF).

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 16/10/2024, Commission cantonale d'éthique de la recherche (CCER) / Cantonal research ethics commission (Rue Adrien-Lachenal 8, Geneva, 1227, Switzerland; +41 (0)22 546 51 01; ccer@etat.ge.ch), ref: 2024-D0031

2. approved 26/06/2024, HUS Regional Medical Research Ethics Committee (HUS Central Archives, PO Box 200, Marjaniementie 74, Iiris Centre, , Helsinki, 00029 HUS, Finland; -; keskuskirjaamo@hus.fi), ref: HUS/4385/2024

Study design

Investigator-initiated prospective randomized controlled open-label multicentre study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Persistent atrial fibrillation and heart failure

Interventions

AF ablation is a routine procedure and may be performed according to the operator's preference (e.g. radiofrequency ablation, cryoablation, pulsed-field ablation etc) but should include pulmonary vein isolation (PVI) and restoration of sinus rhythm as a goal. Patients may be included in the trial if they have had a single previous PVI, but any further redo procedures during the course of the trial are considered CVH endpoints. Rate and/or rhythm control medical therapy may be continued after the ablation procedure, as deemed necessary.

Randomization will be 1:1 using RedCAP with the alternative intervention of CSP + AVNA.

CSP implantation with His bundle pacing (HBP) or left bundle branch area pacing (LBBAP) is currently available in routine clinical practice and may be performed according to the operator's preference but should include conduction system capture or left ventricular septal pacing (LVSP) as a goal. All hardware to be used are commercially available and some will soon receive regulatory approval for CSP.

AVNA is a standard procedure which may be performed during the implantation or as a staged procedure, according to operator preference.

Intervention Type

Procedure/Surgery

Primary outcome(s)

The following primary endpoints are assessed at the last follow-up/study closure:

1. The composite of all-cause death and CVH (superiority hypothesis)
2. The composite of all-cause death and HFH (non-inferiority hypothesis)

Key secondary outcome(s)

The following secondary endpoints are measured using patient medical records at the last follow-up/study closure unless specified otherwise:

1. Individual components of the primary endpoints
2. Cardiovascular mortality
3. Duration of hospitalization for cardiovascular causes
4. Reintervention rate (atrial fibrillation [AF] ablation or device-related)
6. Need for pacemaker implantation (e.g. sinus node dysfunction following AF ablation)
7. Atrioventricular nodal ablation (AVNA) or AF ablation crossovers
8. Sinus rhythm at each follow-up
9. New York Heart Association (NYHA) class at baseline, 1 year and at end of follow-up
10. Quality of life (QOL) questionnaire measured using the Minnesota Living with Heart Failure and EQ-5D-5L at baseline and 1-year
11. Symptom classification for AF measured using the modified European Heart Rhythm Association (EHRA) score
12. Patient-reported outcome measures (PROMs) at 1 year
13. Win ratio composite endpoint analysis
14. Left ventricular ejection fraction (LVEF) at 1 year
15. Left atrial size at 1 year (long axis diameter and 4-chamber surface area)
16. Periprocedural complications (within 1 month of intervention)
17. Long-term complications
18. Healthcare costs and cost-effectiveness

Completion date

01/10/2028

Eligibility

Key inclusion criteria

1. Persistent AF with symptomatic HF despite medical therapy, considered to be suitable for AF ablation, with at most one previous PVI procedure
2. At least one prior hospital admission, or emergency room / HF clinic visit for HF in the past 2 years, with NT-pro-BNP >1000 pg/ml or BNP >250 pg/ml measured at any timepoint during this interval
3. Previous or current rate or rhythm control drug therapy
4. Considered eligible for CSP implantation as an alternative to AF ablation
5. Age > or = 60 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Lower age limit

60 years

Upper age limit

100 years

Sex

All

Key exclusion criteria

1. NYHA Class IV and systolic blood pressure ≤ 80 mmHg despite optimized therapy
2. Life expectancy < 2 years
3. Need for major surgical intervention
4. Myocardial infarction, stroke or percutaneous coronary intervention within the previous 3 months
5. Previously implanted or planned implantation of CRT device or pacemaker. Implantable cardioverter defibrillator (ICD) implantation without a pacing indication is acceptable.
6. Participation in another controlled trial
7. Inability to sign an informed consent form

Date of first enrolment

24/10/2024

Date of final enrolment

20/08/2027

Locations**Countries of recruitment**

United Kingdom

England

Austria

Belgium

Bulgaria

Czech Republic

Finland

France

Germany

Hungary

Italy

Netherlands

Poland

Spain

Switzerland

Study participating centre
University Hospital of Geneva
Rue Gabrielle Perret-Gentil 4,
Geneva
Switzerland
1211

Study participating centre
Inselspital Bern
Freiburgstrasse 20,
Bern
Switzerland
3010

Study participating centre
Univestiy Hospital of Zurich
Rämistrasse 100
Zurich
Switzerland
8091

Study participating centre
University Hospital of Basel
Petersgraben 4
Basel
Switzerland
4031

Study participating centre
IRCCS Policlinico
S. Orsola via Giuseppe Massarenti 9

Bologna
Italy
40138

Study participating centre
Ospedale Santa Maria della Misericordia
Viale Tre Martiri 140
Rovigo
Italy
45100

Study participating centre
Ospedale Maggiore Della Carità Di Novara
Corso Mazzini 18
Novara
Italy
28100

Study participating centre
University Hospital of Ferrara
VIA A. MORO
Cona
Italy
8-44124

Study participating centre
Herzzentrum Leipzig
Strümpellstraße 39
Leipzig
Germany
04289

Study participating centre
Medizinische Fakultät OWL
Georgstr. 11
Bad Oeynhausen
Germany
32545

Study participating centre

Herzzentrum Bremen
Senator-Wessling-Str. 1
Bremen
Germany
28277

Study participating centre

Hospital Universitari i Politècnic la Fe
Avinguda de Fernando Abril Martorell, 106
Valencia
Spain
46026

Study participating centre

Hospital Clínic de Barcelona
Villarroel 170
Barcelona
Spain
08036

Study participating centre

Hospital Clínico Universitario Lozano Blesa
Avenida San Juan Bosco 15
Zaragoza
Spain
50009

Study participating centre

Hospital Universitario La Paz
P.º de la Castellana, 261
Madrid
Spain
28046

Study participating centre

University Hospital Královské Vinohrady
Šrobárova 1150 /50
Prag
Czech Republic
100 00

Study participating centre
Semmelweis University
Üllői út 26
Budapest
Hungary
1085

Study participating centre
Antwerp University Hospital
Drie Eikenstraat 655
Edegem
Belgium
2650

Study participating centre
Universitair Ziekenhuis Gent
Heymanslaan 10
Gent
Belgium
9000

Study participating centre
AZ Sint Jan
Ruddershove 10
Bruges
Belgium
8000

Study participating centre
Jagiellonian University
Jakubowskiego 2
Krakow
Poland
30-688

Study participating centre
St. Joseph's Heart Rhythm Center
Anny Jagiellonki 17

Rzeszów
Poland
35-623

Study participating centre
Heart and Lung Center, Meilahti Hospital
Haartmaninkatu 4
Helsinki
Finland
FI-00029

Study participating centre
Ordensklinikum Elisabethinen
Fadingerstraße 1
Linz
Austria
4020

Study participating centre
LKH-Univ. Klinikum Graz
Auenbruggerplatz 15
Graz
Austria
8036

Study participating centre
Acibadem City Clinic Tokuda University Hospital
bul. "Nikola Y. Vaptsarov" 51B
Sofia
Bulgaria
1407

Study participating centre
Maastricht UMC+
P. Debyelaan 25
Maastricht
Netherlands
6229

Study participating centre
National Heart and Lung Institute, Imperial College London
Guy Scadding Building, Dovehouse St
London
United Kingdom
SW3 6LY

Study participating centre
Service de Cardiologie , hôpital Charles Nicolle
1 rue de Germont
Rouen
France
76031

Sponsor information

Organisation
University Hospital of Geneva

ROR
<https://ror.org/01m1pv723>

Funder(s)

Funder type
Charity

Funder Name
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Alternative Name(s)
Schweizerischer Nationalfonds, Swiss National Science Foundation, Fonds National Suisse de la Recherche Scientifique, Fondo Nazionale Svizzero per la Ricerca Scientifica, Fonds National Suisse, Fondo Nazionale Svizzero, Schweizerische Nationalfonds, The Swiss National Science Foundation (SNSF), SNF, SNSF, FNS

Funding Body Type
Private sector organisation

Funding Body Subtype
Trusts, charities, foundations (both public and private)

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be stored in a publicly available repository (Yareta) without personal data identifiers.

IPD sharing plan summary

Stored in publicly available repository